Publication
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Authors not recorded
Cancer Discov2018PMID 29773717PMC6030433stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerLung Adenocarcinomacivic_curation1.00
- drugAtezolizumabcivic_curation1.00
- drugNivolumabcivic_curation1.00
- drugPembrolizumabcivic_curation1.00
- geneSTK11civic_curation1.00
- variantSTK11 Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 29773717
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| STK11 Mutation1 | ||||||||
| Atezolizumab + Nivolumab + PembrolizumabSubstitutes | Lung Adenocarcinoma | Predictive | B | Supports Resistance | 4 | accepted | EID6441In a retrospective analysis in two separate datasets (Stand Up To Cancer 2 Cohort and Checkmate-057), patients with concomitant KRAS and STK11 mutations had significantly worse response rates, PFS and… (full text at CIViC) PMID 29773717 · Skoulidis et al., 2018 · Open in CIViC | civic |